Principal Financial Group Inc. Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.1% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 84,132 shares of the specialty pharmaceutical company’s stock after selling 3,567 shares during the quarter. Principal Financial Group Inc.’s holdings in ANI Pharmaceuticals were worth $5,358,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after buying an additional 17,460 shares in the last quarter. Rubric Capital Management LP raised its holdings in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after buying an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after buying an additional 33,359 shares in the last quarter. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 10.8% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after buying an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. raised its holdings in shares of ANI Pharmaceuticals by 1.8% during the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock valued at $23,965,000 after buying an additional 7,769 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Price Performance

ANIP opened at $58.48 on Tuesday. The stock’s 50 day simple moving average is $61.82 and its 200 day simple moving average is $64.04. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 36.55 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period last year, the company earned $1.06 EPS. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the sale, the chief operating officer now directly owns 671,620 shares in the company, valued at approximately $42,567,275.60. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the sale, the chief operating officer now directly owns 671,620 shares in the company, valued at approximately $42,567,275.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the sale, the senior vice president now owns 193,226 shares in the company, valued at $12,258,257.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,007 shares of company stock worth $4,091,535. 12.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Truist Financial lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $82.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.